announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimer’s disease (AD), today at the 9 [th] Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego. Data presentations include interim results from the titration….
Posted: 2016-12-09 00:44:00